BTK inhibitors block Bruton's tyrosine kinase, an enzyme that B-cells depend on to survive and multiply. Shutting it down starves B-cell cancers such as chronic lymphocytic leukaemia and mantle cell lymphoma. Ibrutinib was first; the newer, more selective agents were developed to hit BTK harder while touching fewer off-target kinases, which changes their side-effect profile.
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
Plain-English summaries and drug-class explainers are written and reviewed by the Priya Life Science editorial team, led by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 28 Aug 2026.